Crestline Management LP Purchases Shares of 9,140 Qiagen (NYSE:QGEN)

Crestline Management LP acquired a new position in shares of Qiagen (NYSE:QGEN) in the 4th quarter, Holdings Channel reports. The fund acquired 9,140 shares of the company’s stock, valued at approximately $407,000.

Other large investors have also recently made changes to their positions in the company. Brown Brothers Harriman & Co. purchased a new position in Qiagen in the 4th quarter worth $37,000. Geneos Wealth Management Inc. increased its holdings in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after purchasing an additional 251 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock valued at $39,000 after purchasing an additional 526 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Qiagen during the third quarter worth about $53,000. Finally, Smartleaf Asset Management LLC boosted its position in Qiagen by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock valued at $63,000 after buying an additional 835 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on QGEN shares. Robert W. Baird raised their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. UBS Group cut their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. StockNews.com raised Qiagen from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $48.42.

Qiagen Price Performance

NYSE:QGEN opened at $41.87 on Friday. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30. The stock’s 50-day moving average price is $40.67 and its 200-day moving average price is $41.75. The stock has a market capitalization of $9.31 billion, a PE ratio of 116.59, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Qiagen’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $0.44 earnings per share. As a group, equities analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.